Directorate Change

IP2IPO Group PLC 06 April 2004 For Immediate release 6 April 2004 Andrew Beeson steps down as Non-Executive Director IP2IPO Group plc (AIM: IPO), the intellectual property company that commercialises university technology, today announces that Andrew Beeson, Non-Executive Director of IP2IPO, has stepped down from the Board. The Board of IP2IPO would like to thank him for his hard work and the contribution he has made to the Company and wish him all the very best for the future. For more information please contact: IP2IPO David Norwood, Chief Executive Officer 020 7071 4348 Buchanan Communications Mark Court, Mary-Jane Johnson 020 7466 5000 Notes to editors IP2IPO IP2IPO is an intellectual property (IP) company that specialises in commercialising university technology. The Company, which was founded in 2001, has already formed four long-term partnerships with UK universities and listed on AIM in October 2003. IP2IPO's first partnership was with the University of Oxford. In return for an investment of £20 million, IP2IPO has acquired 50 per cent of the University of Oxford's equity in spin-out companies and technology licenses based on intellectual property created at the Chemistry Department until 2015. In November 2003, IP2IPO created a £5 million seed capital fund for investing in spin-out companies across the University of Oxford, not just those originating within the Chemistry Department. In March 2002, IP2IPO entered into a second long-term partnership with the University of Southampton. Under the terms of this partnership, IP2IPO is committed to working with the University of Southampton in the identification and facilitation of spin-out companies from across the University of Southampton and to investing £5 million in early-stage University of Southampton spin-out companies over a four year period in return for equity stakes in those companies. In addition, IP2IPO also received a 20 per cent stake in Southampton Asset Management Limited, a company that has been formed to hold the University's equity stakes in its future spin-out companies. The partnership has a term of at least 25 years. IP2IPO entered into its third long-term partnership in May 2003 with King's College London. IP2IPO will work with King's College London to help identify and progress commercialisation opportunities as well as invest £5 million in seed capital in spin-out companies from King's College London over a five year period in return for equity stakes in those companies. In addition, IP2IPO will receive 20 per cent of King's College London's equity in spin-out companies and technology licenses. The partnership has an initial term of 25 years. In October 2003, IP2IPO announced a fourth partnership with the Centre for Novel Agricultural Products ('CNAP'), based at the University of York. CNAP is a flagship research centre that specialises in plant and microbial gene discovery. Under the terms of the partnership a new company, Amaethon Limited, has been created which has the right to commercialise CNAP's IP for 25 years. IP2IPO has committed to invest £1.15m in Amaethon Limited in return for a one third equity stake in Amaethon Limited (the remaining equity being owned by the University of York) and will also invest in the spin-out companies based on CNAP's IP which Amaethon Limited creates. This information is provided by RNS The company news service from the London Stock Exchange

Companies

IP Group (IPO)
UK 100

Latest directors dealings